Cost-effectiveness of CERAMENT® G in the United States presented at ISPOR conference
Published: 2022-11-07
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that a cost-effectiveness analysis of CERAMENT G was presented at the leading health economic conference ISPOR Europe 2022 on 7 November 2022. The analysis shows that a single-stage protocol with CERAMENT G is a cost-effective strategy to treat bone infection compared to the standard of care in the United States.
When using CERAMENT G instead of antibiotic-loaded PMMA beads, cost reductions are estimated to be USD27,943 on average per patient due to less surgeries and intra- and post-surgical complications. The analysis also shows improved patient quality of life. Greater cost reductions were found compared to other multi-stage protocols to manage bone infection.
The study is based on a health economic model developed to compare healthcare costs benefits from a third-party payer perspective between CERAMENT G and two groups of multi-stage protocols, one of which included antibiotic-loaded PMMA beads. The model simulated one million patients over a two-year horizon from the time they received surgery for bone infection.
“Reducing the number of surgeries in the management of bone infection is a win for patients, hospitals, and society,” said Emil Billbäck, CEO of BONESUPPORT.
About ISPOR
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting is arranged by the Professional Society for Health Economics and Outcomes Research on 6-9 November 2022 in Vienna, Austria. ISPOR Europe 2022 is the leading European conference for Health Economics and Outcomes Research (HEOR).
The poster presentation is published on the ISPOR website.